secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106235
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q2 net loss improves; Zydus deal adds $91M; BOT/BAL Phase 3 starts Q4 2025
--------------------------------------------------------------------------------

- Q2 revenue $25.7M; YTD net loss $56.4M vs $118.3M YoY; cash burn reduced to $45.8M from $76.4M.
- Zydus collaboration closing Q3 2025; $91M upfront capital to support development and regulatory activities.
- BOT/BAL: 42% two-year survival in refractory MSS CRC; FDA agreed to streamlined Phase 3 (BATTMAN) starting Q4 2025.
- Virtual stakeholder meeting on August 27, 2025 to review Q2 results and strategic progress.
- Noetik AI partnership started to refine patient selection via AI algorithms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/0000950170-25-106235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/agen-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer